Sandbox:farnaz: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 17: Line 17:
*B-interferon
*B-interferon
*Teleflunomide
*Teleflunomide
96 patients (174 eyes, 70% females) were included with a mean age at presentation of 30 years


{| class="wikitable"
{| class="wikitable"
!align="center" style="background:#4479BA; color: #FFFFFF;" |Cause
! align="center" style="background:#4479BA; color: #FFFFFF;" |Cause
!align="center" style="background:#4479BA; color: #FFFFFF;" |Symptom
! align="center" style="background:#4479BA; color: #FFFFFF;" |Symptom
!align="center" style="background:#4479BA; color: #FFFFFF;" |Diagnosis
! align="center" style="background:#4479BA; color: #FFFFFF;" |Diagnosis
!align="center" style="background:#4479BA; color: #FFFFFF;" |Treatment
! align="center" style="background:#4479BA; color: #FFFFFF;" |Treatment
|-
|-
|1
|1
Line 41: Line 44:


==References==
==References==
<references />

Revision as of 21:27, 26 January 2018


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farnaz Khalighinejad, MD [2]

Overview

MS is known as multiple sclerosis.

Multiple Sclerosis

ajksfshvanivlk

Type 1:

asdad

Type 2:

The primary therapy for MS may include:[1][2]

  • B-interferon
  • Teleflunomide


96 patients (174 eyes, 70% females) were included with a mean age at presentation of 30 years

Cause Symptom Diagnosis Treatment
1
2
3

References

  1. Kamm CP, Uitdehaag BM, Polman CH (2014). "Multiple sclerosis: current knowledge and future outlook". Eur Neurol. 72 (3–4): 132–41. doi:10.1159/000360528. PMID 25095894.
  2. Schwartz K, Wymbs NF, Huang H, Mealy MA, Pardo CA, Zackowski K; et al. (2017). "Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis". Mult Scler J Exp Transl Clin. 3 (4): 2055217317740145. doi:10.1177/2055217317740145. PMC 5731631. PMID 29270309.